eNOS uncoupling in cardiovascular diseases-the role of oxidative stress and inflammation

Current Pharmaceutical Design

Volumn 20, Issue 22, 2014, Pages 3579-3594

  Karbach, Susanne ^a   Wenzel, Philip ^a   Waisman, Ari ^a   Münzel, Thomas ^a   Daiber, Andreas ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Inflammatory cells; Nitric oxide synthase uncoupling; Oxidative stress; Redox switches in nitric oxide synthase

Indexed keywords

AMINO ACID TRANSPORTER; ANGIOTENSIN II; APOLIPOPROTEIN E; ARGININE; ASCORBIC ACID; CD31 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DIHYDROBIOPTERIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUTATHIONE PEROXIDASE 1; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; HEME OXYGENASE 1; INTERLEUKIN 17; INTERLEUKIN 6; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; N(G) NITROARGININE METHYL ESTER; N(G),N(G) DIMETHYLARGININE; NEBIVOLOL; PENTAERYTHRITYL TETRANITRATE; PEROXYNITRITE; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; SUPEROXIDE DISMUTASE; TETRAHYDROBIOPTERIN; UNINDEXED DRUG; XANTHINE DEHYDROGENASE; XANTHINE OXIDASE;

ACUTE CORONARY SYNDROME; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROTIC PLAQUE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CARDIOVASCULAR DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHEMICAL MODIFICATION; CYTOSOL; DENDRITIC CELL; DIABETES MELLITUS; DOWN REGULATION; ELECTRON SPIN RESONANCE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; GENE OVEREXPRESSION; HEART INFARCTION; HUMAN; HYPERTENSION; INFLAMMATION; INFLAMMATORY CELL; MACROPHAGE; MACROPHAGE ACTIVATION; MITOCHONDRIAL MEMBRANE POTENTIAL; NEUTROPHIL; NITROSATIVE STRESS; NONHUMAN; OXIDATION; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PHAGOCYTE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REPERFUSION INJURY; RESPIRATORY BURST; RHEUMATOID ARTHRITIS; S GLUTATHIONYLATION; SMOOTH MUSCLE FIBER; UPREGULATION; ENZYMOLOGY; METABOLISM; PATHOLOGY;

CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS;

EID: 84907705538     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113196660748     Document Type: Article

References (183)

1. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: Part II: animal and human studies. Circulation 2003, 108: 2034-40.
2. Ischiropoulos H, Beckman JS. Oxidative stress and nitration in neurodegeneration: cause, effect, or association? J Clin Invest 2003, 111: 163-9.
3. Rhee SG. Redox signaling: hydrogen peroxide as intracellular messenger. Exp Mol Med 1999, 31: 53-9.
4. Stamler JS. Redox signaling: nitrosylation and related target interactions of nitric oxide. Cell 1994, 78: 931-6.
5. Ullrich V, Kissner R. Redox signaling: bioinorganic chemistry at its best. J Inorg Biochem 2006, 100: 2079-86.
6. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 1996, 271: C1424-37.
7. Turko IV, Murad F. Protein nitration in cardiovascular diseases. Pharmacol Rev 2002, 54: 619-34.
8. McCord JM, Keele BB, Jr., Fridovich I. An enzyme-based theory of obligate anaerobiosis: the physiological function of superoxide dismutase. Proc Natl Acad Sci USA 1971, 68: 1024-7.
9. Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986, 320: 454-6.
10. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001, 104: 2673-8.
11. Guzik TJ, Hoch NE, Brown KA, et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 2007, 204: 2449-60.
12. Harrison DG, Guzik TJ, Lob HE, et al. Inflammation, immunity, and hypertension. Hypertension, 57: 132-40.
13. Wenzel P, Knorr M, Kossmann S, et al. Lysozyme M-positive monocytes mediate angiotensin II-induced arterial hypertension and vascular dysfunction. Circulation 2011, 124: 1370-1381.
14. Madhur MS, Lob HE, McCann LA, et al. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension 2010, 55: 500-7.
15. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993, 91: 2546-51.
16. Harrison DG, Ohara Y. Physiologic consequences of increased vascular oxidant stresses in hypercholesterolemia and atherosclerosis: implications for impaired vasomotion. Am J Cardiol 1995, 75: 75B-81B.
17. Doerries C, Grote K, Hilfiker-Kleiner D, et al. Critical role of the NAD(P)H oxidase subunit p47phox for left ventricular remodeling/dysfunction and survival after myocardial infarction. Circ Res 2007, 100: 894-903.
18. Landmesser U, Cai H, Dikalov S, et al. Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension 2002, 40: 511-5.
19. Matsuno K, Yamada H, Iwata K, et al. Nox1 is involved in angiotensin II-mediated hypertension: a study in Nox1-deficient mice. Circulation 2005, 112: 2677-85.
20. Dikalova A, Clempus R, Lassegue B, et al. Nox1 overexpression potentiates angiotensin II-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice. Circulation 2005, 112: 2668-76.
21. Wenzel P, Schuhmacher S, Kienhofer J, et al. Manganese superoxide dismutase and aldehyde dehydrogenase deficiency increase mitochondrial oxidative stress and aggravate agedependent vascular dysfunction. Cardiovasc Res 2008, 80: 280-9.
22. Daiber A, Oelze M, Sulyok S, et al. Heterozygous Deficiency of Manganese Superoxide Dismutase in Mice (Mn-SOD+/-): A Novel Approach to Assess the Role of Oxidative Stress for the Development of Nitrate Tolerance. Mol Pharmacol 2005, 68: 579-88.
23. Torzewski M, Ochsenhirt V, Kleschyov AL, et al. Deficiency of Glutathione Peroxidase-1 Accelerates the Progression of Atherosclerosis in Apolipoprotein E-Deficient Mice. Arterioscler Thromb Vasc Biol 2007, 27: 850-7.
24. Daiber A. Redox signaling (cross-talk) from and to mitochondria involves mitochondrial pores and reactive oxygen species. Biochim Biophys Acta 2010, 1797: 897-906.
25. Radi R, Cassina A, Hodara R, Quijano C, Castro L. Peroxynitrite reactions and formation in mitochondria. Free Radic Biol Med 2002, 33: 1451-64.
26. Lin D, Takemoto DJ. Oxidative activation of protein kinase Cgamma through the C1 domain. Effects on gap junctions. J Biol Chem 2005, 280: 13682-93.
27. Zhang DX, Chen YF, Campbell WB, Zou AP, Gross GJ, Li PL. Characteristics and superoxide-induced activation of reconstituted myocardial mitochondrial ATP-sensitive potassium channels. Circ Res 2001, 89: 1177-83.
28. Brandes RP. Triggering mitochondrial radical release: a new function for NADPH oxidases. Hypertension 2005, 45: 847-8.
29. Di Lisa F, Canton M, Menabo R, Kaludercic N, Bernardi P. Mitochondria and cardioprotection. Heart Fail Rev 2007, 12: 249-60.
30. Dikalov S. Cross talk between mitochondria and NADPH oxidases. Free Radic Biol Med 2011, 51: 1289-301.
31. Schulz E, Wenzel P, Munzel T, Daiber A. Mitochondrial redox signaling: interaction of mitochondrial reactive oxygen species with other sources of oxidative stress. Antioxid Redox Signal 2012.
32. Ryan MG, Balendran A, Harrison R, Wolstenholme A, Bulkley GB. Xanthine oxidoreductase: dehydrogenase to oxidase conversion. Biochem Soc Trans 1997, 25: 530S.
33. Nishino T. The conversion from the dehydrogenase type to the oxidase type of rat liver xanthine dehydrogenase by modification of cysteine residues with fluorodinitrobenzene. J Biol Chem 1997, 272: 29859-64.
34. Landmesser U, Spiekermann S, Preuss C, et al. Angiotensin II induces endothelial xanthine oxidase activation: role for endothelial dysfunction in patients with coronary disease. Arterioscler Thromb Vasc Biol 2007, 27: 943-8.
35. Li H, Witte K, August M, et al. Reversal of endothelial nitric oxide synthase uncoupling and up-regulation of endothelial nitric oxide synthase expression lowers blood pressure in hypertensive rats. J Am Coll Cardiol 2006, 47: 2536-44.
36. Mollnau H, Wendt M, Szocs K, et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res 2002, 90: E58-65.
37. Guzik TJ, Mussa S, Gastaldi D, et al. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 2002, 105: 1656-62.
38. Loomis ED, Sullivan JC, Osmond DA, Pollock DM, Pollock JS. Endothelin mediates superoxide production and vasoconstriction through activation of NADPH oxidase and uncoupled nitric-oxide synthase in the rat aorta. J Pharmacol Exp Ther 2005, 315: 1058-64.
39. Wenzel P, Schulz E, Oelze M, et al. AT1-receptor blockade by telmisartan upregulates GTP-cyclohydrolase I and protects eNOS in diabetic rats. Free Radic Biol Med 2008, 45: 619-26.
40. Knorr M, Hausding M, Kroller-Schuhmacher S, et al. Nitroglycerin-Induced Endothelial Dysfunction and Tolerance Involve Adverse Phosphorylation and S-Glutathionylation of Endothelial Nitric Oxide Synthase: Beneficial Effects of Therapy With the AT1 Receptor Blocker Telmisartan. Arterioscler Thromb Vasc Biol 2011.
41. Landmesser U, Dikalov S, Price SR, et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 2003, 111: 1201-9.
42. Xu J, Xie Z, Reece R, Pimental D, Zou MH. Uncoupling of endothelial nitric oxidase synthase by hypochlorous acid: role of NAD(P)H oxidase-derived superoxide and peroxynitrite. Arterioscler Thromb Vasc Biol 2006, 26: 2688-95.
43. Zhang M, Song P, Xu J, Zou MH. Activation of NAD(P)H oxidases by thromboxane A2 receptor uncouples endothelial nitric oxide synthase. Arterioscler Thromb Vasc Biol 2011, 31: 125-32.
44. Heitzer T, Just H, Munzel T. Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. Circulation 1996, 94: 6-9.
45. Jankov RP, Kantores C, Pan J, Belik J. Contribution of xanthine oxidase-derived superoxide to chronic hypoxic pulmonary hypertension in neonatal rats. Am J Physiol Lung Cell Mol Physiol 2008, 294: L233-45.
46. Desco MC, Asensi M, Marquez R, et al. Xanthine oxidase is involved in free radical production in type 1 diabetes: protection by allopurinol. Diabetes 2002, 51: 1118-24.
47. Dikalova AE, Bikineyeva AT, Budzyn K, et al. Therapeutic targeting of mitochondrial superoxide in hypertension. Circ Res 2010, 107: 106-16.
48. Adlam VJ, Harrison JC, Porteous CM, et al. Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury. Faseb J 2005, 19: 1088-95.
49. Hayashi T, Juliet PA, Kano-Hayashi H, et al. NADPH oxidase inhibitor, apocynin, restores the impaired endothelial-dependent and-independent responses and scavenges superoxide anion in rats with type 2 diabetes complicated by NO dysfunction. Diabetes Obes Metab 2005, 7: 334-43.
50. Li L, Fink GD, Watts SW, et al. Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in lowrenin hypertension. Circulation 2003, 107: 1053-8.
51. Dodd OJ, Pearse DB. Effect of the NADPH oxidase inhibitor apocynin on ischemia-reperfusion lung injury. Am J Physiol Heart Circ Physiol 2000, 279: H303-12.
52. Munzel T, Daiber A, Ullrich V, Mulsch A. Vascular Consequences of Endothelial Nitric Oxide Synthase Uncoupling for the Activity and Expression of the Soluble Guanylyl Cyclase and the cGMPDependent Protein Kinase. Arterioscler Thromb Vasc Biol 2005, 25: 1551-7.
53. Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 2006, 113: 1708-14.
54. Miller RT, Martasek P, Roman LJ, Nishimura JS, Masters BS. Involvement of the reductase domain of neuronal nitric oxide synthase in superoxide anion production. Biochemistry 1997, 36: 15277-84.
55. Vasquez-Vivar J, Martasek P, Hogg N, et al. Electron spin resonance spin-trapping detection of superoxide generated by neuronal nitric oxide synthase. Methods Enzymol 1999, 301: 169-77.
56. Pou S, Keaton L, Surichamorn W, Rosen GM. Mechanism of superoxide generation by neuronal nitric-oxide synthase. J Biol Chem 1999, 274: 9573-80.
57. Vasquez-Vivar J, Hogg N, Martasek P, Karoui H, Pritchard KA, Jr., Kalyanaraman B. Tetrahydrobiopterin-dependent inhibition of superoxide generation from neuronal nitric oxide synthase. J Biol Chem 1999, 274: 26736-42.
58. Xia Y, Zweier JL. Superoxide and peroxynitrite generation from inducible nitric oxide synthase in macrophages. Proc Natl Acad Sci USA 1997, 94: 6954-8.
59. Xia Y, Roman LJ, Masters BS, Zweier JL. Inducible nitric-oxide synthase generates superoxide from the reductase domain. J Biol Chem 1998, 273: 22635-9.
60. Miller AA, Megson IL, Gray GA. Inducible nitric oxide synthasederived superoxide contributes to hypereactivity in small mesenteric arteries from a rat model of chronic heart failure. Br J Pharmacol 2000, 131: 29-36.
61. Ungvari Z, Csiszar A, Edwards JG, et al. Increased superoxide production in coronary arteries in hyperhomocysteinemia: role of tumor necrosis factor-alpha, NAD(P)H oxidase, and inducible nitric oxide synthase. Arterioscler Thromb Vasc Biol 2003, 23: 418-24.
62. Vasquez-Vivar J, Kalyanaraman B, Martasek P, et al. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci USA 1998, 95: 9220-5.
63. Xia Y, Tsai AL, Berka V, Zweier JL. Superoxide generation from endothelial nitric-oxide synthase. A Ca2+/calmodulin-dependent and tetrahydrobiopterin regulatory process. J Biol Chem 1998, 273: 25804-8.
64. Milstien S, Katusic Z. Oxidation of tetrahydrobiopterin by peroxynitrite: implications for vascular endothelial function. Biochem Biophys Res Commun 1999, 263: 681-4.
65. Kuzkaya N, Weissmann N, Harrison DG, Dikalov S. Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase. J Biol Chem 2003, 278: 22546-54.
66. Whitsett J, Picklo MJ, Sr., Vasquez-Vivar J. 4-Hydroxy-2-nonenal increases superoxide anion radical in endothelial cells via stimulated GTP cyclohydrolase proteasomal degradation. Arterioscler Thromb Vasc Biol 2007, 27: 2340-7.
67. Baker TA, Milstien S, Katusic ZS. Effect of vitamin C on the availability of tetrahydrobiopterin in human endothelial cells. J Cardiovasc Pharmacol 2001, 37: 333-8.
68. d'Uscio LV, Milstien S, Richardson D, Smith L, Katusic ZS. Longterm vitamin C treatment increases vascular tetrahydrobiopterin levels and nitric oxide synthase activity. Circ Res 2003, 92: 88-95.
69. Heitzer T, Finckh B, Albers S, Krohn K, Kohlschutter A, Meinertz T. Beneficial effects of alpha-lipoic acid and ascorbic acid on endothelium-dependent, nitric oxide-mediated vasodilation in diabetic patients: relation to parameters of oxidative stress. Free Radic Biol Med 2001, 31: 53-61.
70. Alp NJ, Channon KM. Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. Arterioscler Thromb Vasc Biol 2004, 24: 413-20.
71. Alp NJ, McAteer MA, Khoo J, Choudhury RP, Channon KM. Increased endothelial tetrahydrobiopterin synthesis by targeted transgenic GTP-cyclohydrolase I overexpression reduces endothelial dysfunction and atherosclerosis in ApoE-knockout mice. Arterioscler Thromb Vasc Biol 2004, 24: 445-50.
72. Meininger CJ, Cai S, Parker JL, et al. GTP cyclohydrolase I gene transfer reverses tetrahydrobiopterin deficiency and increases nitric oxide synthesis in endothelial cells and isolated vessels from diabetic rats. Faseb J 2004, 18: 1900-2.
73. Cai S, Khoo J, Mussa S, Alp NJ, Channon KM. Endothelial nitric oxide synthase dysfunction in diabetic mice: importance of tetrahydrobiopterin in eNOS dimerisation. Diabetologia 2005, 48: 1933-40.
74. Chalupsky K, Cai H. Endothelial dihydrofolate reductase: critical for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase. Proc Natl Acad Sci USA 2005, 102: 9056-61.
75. Ionova IA, Vasquez-Vivar J, Whitsett J, et al. Deficient BH4 production via de novo and salvage pathways regulates NO responses to cytokines in adult cardiac myocytes. Am J Physiol Heart Circ Physiol 2008, 295: H2178-87.
76. Heitzer T, Brockhoff C, Mayer B, et al. Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers : evidence for a dysfunctional nitric oxide synthase. Circ Res 2000, 86: E36-41.
77. Heitzer T, Krohn K, Albers S, Meinertz T. Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with Type II diabetes mellitus. Diabetologia 2000, 43: 1435-8.
78. Antoniades C, Shirodaria C, Warrick N, et al. 5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation 2006, 114: 1193-201.
79. Gori T, Burstein JM, Ahmed S, et al. Folic acid prevents nitroglycerin-induced nitric oxide synthase dysfunction and nitrate tolerance: a human in vivo study. Circulation 2001, 104: 1119-23.
80. Laursen JB, Somers M, Kurz S, et al. Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation 2001, 103: 1282-8.
81. Schuhmacher S, Wenzel P, Schulz E, et al. Pentaerythritol tetranitrate improves angiotensin II-induced vascular dysfunction via induction of heme oxygenase-1. Hypertension 2010, 55: 897-904.
82. Zou MH, Shi C, Cohen RA. Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J Clin Invest 2002, 109: 817-26.
83. Stocker R, Huang A, Jeranian E, et al. Hypochlorous acid impairs endothelium-derived nitric oxide bioactivity through a superoxidedependent mechanism. Arterioscler Thromb Vasc Biol 2004, 24: 2028-33.
84. Wenzel P, Daiber A, Oelze M, et al. Mechanisms underlying recoupling of eNOS by HMG-CoA reductase inhibition in a rat model of streptozotocin-induced diabetes mellitus. Atherosclerosis 2008, 198: 65-76.
85. Crow JP, Beckman JS, McCord JM. Sensitivity of the essential zinc-thiolate moiety of yeast alcohol dehydrogenase to hypochlorite and peroxynitrite. Biochemistry 1995, 34: 3544-52.
86. Daiber A, Frein D, Namgaladze D, Ullrich V. Oxidation and nitrosation in the nitrogen monoxide/superoxide system. J Biol Chem 2002, 277: 11882-8.
87. Wenzel P, Hink U, Oelze M, et al. Role of reduced lipoic acid in the redox regulation of mitochondrial aldehyde dehydrogenase (ALDH-2) activity. Implications for mitochondrial oxidative stress and nitrate tolerance. J Biol Chem 2007, 282: 792-9.
88. Zee RS, Yoo CB, Pimentel DR, et al. Redox regulation of sirtuin-1 by S-glutathiolation. Antioxid Redox Signal 2010, 13: 1023-32.
89. Adachi T, Weisbrod RM, Pimentel DR, et al. S-Glutathiolation by peroxynitrite activates SERCA during arterial relaxation by nitric oxide. Nat Med 2004, 10: 1200-7.
90. Chen CA, Wang TY, Varadharaj S, et al. S-glutathionylation uncouples eNOS and regulates its cellular and vascular function. Nature 2010, 468: 1115-8.
91. Chen CA, Lin CH, Druhan LJ, Wang TY, Chen YR, Zweier JL. Superoxide induces eNOS protein Thiyl radical formation: a novel mechanism regulating eNOS function and coupling. J Biol Chem 2011.
92. Schuhmacher S, Oelze M, Bollmann F, et al. Vascular Dysfunction in Experimental Diabetes Is Improved by Pentaerithrityl Tetranitrate but not Isosorbide-5-Mononitrate Therapy. Diabetes 2011, 60: 2608-16.
93. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Aktdependent phosphorylation. Nature 1999, 399: 601-5.
94. Loot AE, Schreiber JG, Fisslthaler B, Fleming I. Angiotensin II impairs endothelial function via tyrosine phosphorylation of the endothelial nitric oxide synthase. J Exp Med 2009, 206: 2889-96.
95. Fleming I, Fisslthaler B, Dimmeler S, Kemp BE, Busse R. Phosphorylation of Thr(495) regulates Ca(2+)/calmodulindependent endothelial nitric oxide synthase activity. Circ Res 2001, 88: E68-75.
96. Lin MI, Fulton D, Babbitt R, et al. Phosphorylation of threonine 497 in endothelial nitric-oxide synthase coordinates the coupling of L-arginine metabolism to efficient nitric oxide production. J Biol Chem 2003, 278: 44719-26.
97. Rathore R, Zheng YM, Niu CF, et al. Hypoxia activates NADPH oxidase to increase [ROS]i and [Ca2+]i through the mitochondrial ROS-PKCepsilon signaling axis in pulmonary artery smooth muscle cells. Free Radic Biol Med 2008, 45: 1223-31.
98. Boger RH. Association of asymmetric dimethylarginine and endothelial dysfunction. Clin Chem Lab Med 2003, 41: 1467-72.
99. Sydow K, Munzel T. ADMA and oxidative stress. Atheroscler Suppl 2003, 4: 41-51.
100. Schnabel R, Blankenberg S, Lubos E, et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 2005, 97: e53-9.
101. Boger RH. When the endothelium cannot say 'NO' anymore. ADMA, an endogenous inhibitor of NO synthase, promotes cardiovascular disease. Eur Heart J 2003, 24: 1901-2.
102. Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 2000, 20: 2032-7.
103. Jia SJ, Jiang DJ, Hu CP, et al. Lysophosphatidylcholine-induced elevation of asymmetric dimethylarginine level by the NADPH oxidase pathway in endothelial cells. Vascul Pharmacol 2006, 44: 143-8.
104. Jacobi J, Maas R, Cordasic N, et al. Role of asymmetric dimethylarginine for angiotensin II-induced target organ damage in mice. Am J Physiol Heart Circ Physiol 2008, 294: H1058-66.
105. Leiper J, Murray-Rust J, McDonald N, Vallance P. S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proc Natl Acad Sci USA 2002, 99: 13527-32.
106. Liang J, Zheng Z, Wang M, et al. Myeloperoxidase (MPO) and interleukin-17 (IL-17) plasma levels are increased in patients with acute coronary syndromes. The Journal of international medical research 2009, 37: 862-6.
107. Slenzka A, Habermeier A, Simon A, Closs EI. Reduced ADMA export-increased ADMA accumulation? . Naunyn-Schmiedeberg´s Arch Pharmacol 2010, 381: 56.
108. Slenzka A, Unger G, Habermeier A, Closs EI. Removal of intracellular asymmetric dimethyl-L-arginine (ADMA) requires system y(+)L membrane transporter-despite significant activity of the metabolising enzyme dimethylarginine dimethylaminohydrolase (DDAH). N aunyn-Schmiedeberg´s Arch Pharmacol 2011, 383: 30 (P077).
109. Strobel J, Mieth M, Endress B, et al. Interaction of the cardiovascular risk marker asymmetric dimethylarginine (ADMA) with the human cationic amino acid transporter 1 (CAT1). J Mol Cell Cardiol 2012.
110. Schulz E, Jansen T, Wenzel P, Daiber A, Munzel T. Nitric oxide, tetrahydrobiopterin, oxidative stress, and endothelial dysfunction in hypertension. Antioxid Redox Signal 2008, 10: 1115-26.
111. Alp NJ, Mussa S, Khoo J, et al. Tetrahydrobiopterin-dependent preservation of nitric oxide-mediated endothelial function in diabetes by targeted transgenic GTP-cyclohydrolase I overexpression. J Clin Invest 2003, 112: 725-35.
112. Abraham NG, Kappas A. Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev 2008, 60: 79-127.
113. Oelze M, Schuhmacher S, Daiber A. Organic nitrates and nitrate resistance in diabetes: the role of vascular dysfunction and oxidative stress with emphasis on antioxidant properties of pentaerithrityl tetranitrate. Exp Diabetes Res 2010, 2010: 213176.
114. Jansen T, Hortmann M, Oelze M, et al. Conversion of biliverdin to bilirubin by biliverdin reductase contributes to endothelial cell protection by heme oxygenase-1-evidence for direct and indirect antioxidant actions of bilirubin. J Mol Cell Cardiol 2010, 49: 186-95.
115. Munzel T, Daiber A, Mulsch A. Explaining the phenomenon of nitrate tolerance. Circ Res 2005, 97: 618-28.
116. Gori T, Daiber A. Non-hemodynamic effects of organic nitrates and the distinctive characteristics of pentaerithrityl tetranitrate. Am J Cardiovasc Drugs 2009, 9: 7-15.
117. Oppermann M, Balz V, Adams V, et al. Pharmacological induction of vascular extracellular superoxide dismutase expression in vivo. J Cell Mol Med 2009, 13: 1271-8.
118. Pautz A, Rauschkolb P, Schmidt N, et al. Effects of nitroglycerin or pentaerithrityl tetranitrate treatment on the gene expression in rat hearts: evidence for cardiotoxic and cardioprotective effects. Physiol Genomics 2009, 38: 176-85.
119. Oelze M, Daiber A, Brandes RP, et al. Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats. Hypertension 2006, 48: 677-84.
120. Schuhmacher S, Foretz M, Knorr M, et al. alpha1AMP-activated protein kinase preserves endothelial function during chronic angiotensin II treatment by limiting Nox2 upregulation. Arterioscler Thromb Vasc Biol 2011, 31: 560-6.
121. Fukai T, Folz RJ, Landmesser U, Harrison DG. Extracellular superoxide dismutase and cardiovascular disease. Cardiovasc Res 2002, 55: 239-49.
122. Shuvaev VV, Christofidou-Solomidou M, Bhora F, et al. Targeted detoxification of selected reactive oxygen species in the vascular endothelium. J Pharmacol Exp Ther 2009, 331: 404-11.
123. Fernandez C, Hattan CM, Kerns RJ. Semi-synthetic heparin derivatives: chemical modifications of heparin beyond chain length, sulfate substitution pattern and N-sulfo/N-acetyl groups. Carbohydr Res 2006, 341: 1253-65.
124. Chen AF, Chen DD, Daiber A, Fet al. Free radical biology of the cardiovascular system. Clin Sci (Lond) 2012, 123: 73-91.
125. Cave AC, Brewer AC, Narayanapanicker A, et al. NADPH oxidases in cardiovascular health and disease. Antioxidants & redox signaling 2006, 8: 691-728.
126. Herrera J, Ferrebuz A, MacGregor EG, Rodriguez-Iturbe B. Mycophenolate mofetil treatment improves hypertension in patients with psoriasis and rheumatoid arthritis. Journal of the American Society of Nephrology : JASN 2006, 17: S218-25.
127. Dale DC, Boxer L, Liles WC. The phagocytes: neutrophils and monocytes. Blood 2008, 112: 935-45.
128. Chatterjee M, Saluja R, Tewari S, Barthwal MK, Goel SK, Dikshit M. Augmented nitric oxide generation in neutrophils: oxidative and pro-inflammatory implications in hypertension. Free radical research 2009, 43: 1195-204.
129. Baldus S, Heeschen C, Meinertz T, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003, 108: 1440-5.
130. Baldus S, Rudolph V, Roiss M, et al. Heparins increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase. Circulation 2006, 113: 1871-8.
131. Eiserich JP, Baldus S, Brennan ML, et al. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science 2002, 296: 2391-4.
132. van Leeuwen M, Gijbels MJ, Duijvestijn A, et al. Accumulation of myeloperoxidase-positive neutrophils in atherosclerotic lesions in LDLR-/-mice. Arteriosclerosis, thrombosis, and vascular biology 2008, 28: 84-9.
133. Bradley PP, Priebat DA, Christensen RD, Rothstein G. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. The Journal of investigative dermatology 1982, 78: 206-9.
134. Zhang R, Brennan ML, Fu X, et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001, 286: 2136-42.
135. Brennan ML, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. The New England journal of medicine 2003, 349: 1595-604.
136. von Leitner EC, Klinke A, Atzler D, et al. Pathogenic cycle between the endogenous nitric oxide synthase inhibitor asymmetrical dimethylarginine and the leukocyte-derived hemoprotein myeloperoxidase. Circulation 2011, 124: 2735-45.
137. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annual review of immunology 2009, 27: 485-517.
138. Iwakura Y, Ishigame H, Saijo S, Nakae S. Functional specialization of interleukin-17 family members. Immunity 2011, 34: 149-62.
139. von Vietinghoff S, Ley K. Interleukin 17 in vascular inflammation. Cytokine Growth Factor Rev 2010, 21: 463-9.
140. Schrader LI, Kinzenbaw DA, Johnson AW, Faraci FM, Didion SP. IL-6 deficiency protects against angiotensin II induced endothelial dysfunction and hypertrophy. Arteriosclerosis, thrombosis, and vascular biology 2007, 27: 2576-81.
141. Hashmi S, Zeng QT. Role of interleukin-17 and interleukin-17-induced cytokines interleukin-6 and interleukin-8 in unstable coronary artery disease. Coronary artery disease 2006, 17: 699-706.
142. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000, 101: 1767-72.
143. Pietrowski E, Bender B, Huppert J, White R, Luhmann HJ, Kuhlmann CR. Pro-inflammatory effects of interleukin-17A on vascular smooth muscle cells involve NAD(P)Hoxidase derived reactive oxygen species. Journal of vascular research 2011, 48: 52-8.
144. Zhu F, Wang Q, Guo C, et al. IL-17 induces apoptosis of vascular endothelial cells: a potential mechanism for human acute coronary syndrome. Clinical Immunology 2011, 141: 152-60.
145. Huppert J, Closhen D, Croxford A, et al. Cellular mechanisms of IL-17-induced blood-brain barrier disruption. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2010, 24: 1023-34.
146. Roussel L, Houle F, Chan C, et al. IL-17 promotes p38 MAPKdependent endothelial activation enhancing neutrophil recruitment to sites of inflammation. Journal of immunology 2010, 184: 4531-7.
147. Balsari A, Marolda R, Gambacorti-Passerini C, et al. Systemic administration of autologous, alloactivated helper-enriched lymphocytes to patients with metastatic melanoma of the lung. A phase I study. Cancer immunology, immunotherapy : CII 1986, 21: 148-55.
148. Hoch NE, Guzik TJ, Chen W, et al. Regulation of T-cell function by endogenously produced angiotensin II. American journal of physiology. Regulatory, integrative and comparative physiology 2009, 296: R208-16.
149. Geiger H. T-cells in angiotensin-II-induced vascular damage. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association-European Renal Association 2008, 23: 1107-8.
150. Cuttica MJ, Langenickel T, Noguchi A, Machado RF, Gladwin MT, Boehm M. Perivascular T-cell infiltration leads to sustained pulmonary artery remodeling after endothelial cell damage. American journal of respiratory cell and molecular biology 2011, 45: 62-71.
151. Taraseviciene-Stewart L, Nicolls MR, Kraskauskas D, et al. Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling. American journal of respiratory and critical care medicine 2007, 175: 1280-9.
152. Richards H, Williams A, Jones E, et al. Novel role of regulatory T cells in limiting early neutrophil responses in skin. Immunology 2010, 131: 583-92.
153. Liu G, Zhao Y. Toll-like receptors and immune regulation: their direct and indirect modulation on regulatory CD4+ CD25+ T cells. Immunology 2007, 122: 149-56.
154. Barhoumi T, Kasal DA, Li MW, et al. T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertension 2011, 57: 469-76.
155. Kassan M, Galan M, Partyka M, Trebak M, Matrougui K. Interleukin-10 released by CD4(+)CD25(+) natural regulatory T cells improves microvascular endothelial function through inhibition of NADPH oxidase activity in hypertensive mice. Arterioscler Thromb Vasc Biol 2011, 31: 2534-42.
156. Kasal DA, Barhoumi T, Li MW, et al. T regulatory lymphocytes prevent aldosterone-induced vascular injury. Hypertension 2012, 59: 324-30.
157. Schlienger K, Craighead N, Lee KP, Levine BL, June CH. Efficient priming of protein antigen-specific human CD4(+) T cells by monocyte-derived dendritic cells. Blood 2000, 96: 3490-8.
158. Thery C, Amigorena S. The cell biology of antigen presentation in dendritic cells. Current opinion in immunology 2001, 13: 45-51.
159. Song J, Lei FT, Xiong X, Haque R. Intracellular signals of T cell costimulation. Cellular & molecular immunology 2008, 5: 239-47.
160. Vinh A, Chen W, Blinder Y, et al. Inhibition and genetic ablation of the B7/CD28 T-cell costimulation axis prevents experimental hypertension. Circulation 2010, 122: 2529-37.
161. Lapteva N, Ide K, Nieda M, et al. Activation and suppression of renin-angiotensin system in human dendritic cells. Biochemical and biophysical research communications 2002, 296: 194-200.
162. Herrada AA, Contreras FJ, Marini NP, et al. Aldosterone promotes autoimmune damage by enhancing Th17-mediated immunity. Journal of immunology 2010, 184: 191-202.
163. Gotsman I, Sharpe AH, Lichtman AH. T-cell costimulation and coinhibition in atherosclerosis. Circ Res 2008, 103: 1220-31.
164. LaMarca B, Wallace K, Herse F, et al. Hypertension in response to placental ischemia during pregnancy: role of B lymphocytes. Hypertension 2011, 57: 865-71.
165. Ulrich S, Taraseviciene-Stewart L, Huber LC, Speich R, Voelkel N. Peripheral blood B lymphocytes derived from patients with idiopathic pulmonary arterial hypertension express a different RNA pattern compared with healthy controls: a cross sectional study. Respiratory research 2008, 9: 20.
166. Wang X, Stormont R, Liu X, Brock A, Stewart M, Sun Z. Genetic B Lymphocyte Deficiency Attenuates Cold-induced Hypertension. FASEB J 2010, 24: 792.6.
167. Rosskopf D, Hartung K, Hense J, Siffert W. Enhanced immunoglobulin formation of immortalized B cells from hypertensive patients. Hypertension 1995, 26: 432-5.
168. Soltesz P, Kerekes G, Der H, et al. Comparative assessment of vascular function in autoimmune rheumatic diseases: considerations of prevention and treatment. Autoimmunity reviews 2011, 10: 416-25.
169. Murdaca G, Colombo BM, Cagnati P, Gulli R, Spano F, Puppo F. Endothelial dysfunction in rheumatic autoimmune diseases. Atherosclerosis 2012.
170. Vena GA, Vestita M, Cassano N. Psoriasis and cardiovascular disease. Dermatologic therapy 2010, 23: 144-51.
171. Hak AE, Karlson EW, Feskanich D, Stampfer MJ, Costenbader KH. Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses' health study. Arthritis and rheumatism 2009, 61: 1396-402.
172. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. European heart journal 2010, 31: 1000-6.
173. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidencebased recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Annals of the rheumatic diseases 2010, 69: 325-31.
174. Sodergren A, Karp K, Boman K, et al. Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness. Arthritis research & therapy 2010, 12: R158.
175. Balci DD, Balci A, Karazincir S, et al. Increased carotid artery intima-media thickness and impaired endothelial function in psoriasis. Journal of the European Academy of Dermatology and Venereology : JEADV 2009, 23: 1-6.
176. Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. The Journal of investigative dermatology 2009, 129: 1339-50.
177. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. The New England journal of medicine 2012, 366: 1190-9.
178. Papp KA, Leonardi C, Menter A, et al. Brodalumab, an antiinterleukin-17-receptor antibody for psoriasis. The New England journal of medicine 2012, 366: 1181-9.
179. Crispin JC, Tsokos GC. IL-17 in systemic lupus erythematosus. Journal of biomedicine & biotechnology 2010, 2010: 943254.
180. Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology 2012, 51 Suppl 5: v3-v11.
181. Pasceri V, Yeh ET. A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation 1999, 100: 2124-6.
182. Daiber A, Münzel T. Oxidativer Stress, Redoxregulation und NOBioverfügbarkeit -experimentelle und klinische Aspekte. Steinkopff Verlag Darmstadt 2006, Darmstadt, Germany.
183. Boger RH. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res 2003, 59: 824-33.